EUCTR2014-003865-11-IT进行中（未招募）1 期
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs.Placebo Plus Standard of Care in Subjects with Light Chain (AL)Amyloidosis - A study to see how effective and safe NEO001 is when given together with the standard treatment in c
PROTHENA THERAPEUTICS LIMITED0 个研究点目标入组 260 人开始时间: 2021年1月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria:
- •1. Aged = 18 years
- •2. Newly diagnosed and AL amyloidosis treatment naïve
- •3.Bone marrow demonstrating clonal plasma cells
- •4. Confirmed diagnosis of AL amyloidosis by the following:
- •Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue
- •specimens OR characteristic electron microscopy appearance AND
- •Confirmatory immunohistochemistry OR mass spectroscopy of AL amyloidosis
- •5.Confirmed diagnosis of AL amyloidosis by mass spectrometry or immunoelectron microscopy of amyloid material in tissue biopsy if the subject meets any of the following:
- •is black or African American
- •is over 75 years of age with concurrent monoclonal gammopathy
- •has a history of familial amyloidosis and has concurrent monoclonal gammopathy
- •If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3- diphosphono-1,2 propanodicarboxylic acid (99mTc-DPD; Rapezzi 2011), hydroxymethylenediphosphonate (99mTc-HMDP; Galat 2015), or pyrophosphate (99mTc-PYP; Bokhari 2013) scintigraphy
- •6.Cardiac involvement as defined by all of the following:
- •Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure
- •Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole > 12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening
- •NT-proBNP = 650 pg/mL and = 8500 pg/mL
- •7. Planned first-line chemotherapy contains bortezomib administered weekly and SC
- •8.Adequate bone marrow reserve, hepatic function, and renal function, as demonstrated by:
- •absolute neutrophil count (ANC) = 1.0 x10^9/L
- •platelet count = 75 x 10^9/L
- •hemoglobin = 9 g/dL
- •total bilirubin = 2 times the upper limit of normal (x ULN)
- •aspartate aminotransferase (AST) / serum glutamic oxaloacetic transaminase (SGOT) = 3 x ULN
- •alanine aminotransferase (ALT) / serum glutamic pyruvic transaminase (SGPT) = 3 x ULN
- •alkaline phosphatase (ALP) = 5 x ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
- •estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73 m^2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- •9.Seated systolic blood pressure (BP) 90-180 mmHg
- •10.Distance walked during each Screening 6MWT is =30 meters and = 550 meters
- •11.Women of childbearing potential (WOCBP) must have two negative
- •pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
- •12.Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
排除标准
- •Subjects must meet none of the following criteria:
- •1.Non-AL amyloidosis
- •2.NT-proBNP < 650 pg/mL or > 8,500 pg/mL
- •3.Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma (see Appendix 5)
- •*Note that subjects who meet the IMWG definition of symptomatic multiple myeloma with signs and/or symptoms attributable only to associated amyloidosis and who do not otherwise meet the criteria for diagnosis of smoldering myeloma are potentially eligible upon approval of the Sponsor.
- •4.Subject is eligible for and plans to undergo ASCT or organ transplant
- •5.Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject's ability to safely receive treatment or complete study assessments
- •6.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit
- •7.Severe valvular stenosis (e.g. aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease
- •8.ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:
- •First degree AV-block
- •Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)
- •Right or left bundle branch block
- •Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e.,
- •>110 bpm] ventricular rate is not allowed [determined by an average of three beats in Lead II or three representative beats if Lead II is not representative of the overall ECG])
- •9.Peripheral neuropathy assessed as National Cancer Institute-Common Terminology Criteria for Adverse Events ( NCI-CTCAE) Grade 2 with pain, Grade 3 or Grade 4
- •10.Subject is receiving oral or IV antibiotics, antifungals or antivirals within 1 week of Month 1-Day 1 with the exception of prophylactic oral agents
- •11.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1
- •12.Prior radiotherapy within 4 weeks of Month 1-Day 1
- •13.Major surgery within 4 weeks of Month 1-Day 1 or planned major surgery during the study
- •14.Active malignancy with the exception of any of the following:
- •Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer
- •Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for 2 years
- •Low-risk prostate cancer with Gleason score < 7 and prostate-specific antigen < 10 mg/mL
- •Any other cancer from which the subject has been disease-free for = 2 years
- •15.History of severe allergy to any of the components of NEOD001 such as histidine/L histidine hydrochloride monohydrate, trehalose
- •dehydrate, or polysorbate 20 or history of Grade = 3 infusion-related AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine (or an equivalent H1 antihistamine) or acetaminophen (or its equivalent, paracetamol)
- •16.Known or history of uncontrolled, active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection
- •17.Prior treatment with plasma cell-directed chemotherapy, NEOD001, 11-1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid
- •18.Treatment with another investigational agent within 30 days of Month 1-Day 1
- •19.Women who are pregnant or lactating
- •20.Any condition which could interfere with, or the treatment for which mig
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of bimekizumab compared to placebo and an active comparator in adult subjects with moderate to severe chronic plaque psoriasisModerate to Severe Chronic Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2016-003425-42-ITCB Biopharma SR567
进行中（未招募）
不适用
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerAdvanced MET-Positive Gastric, Lower Esophageal or Gastroesophageal Junction AdenocarcinomaMedDRA version: 16.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10017761Term: Gastric cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10017766Term: Gastric cancer stage IV NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10017765Term: Gastric cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004923-11-HUAmgen Inc450
进行中（未招募）
1 期
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- And Active-Controlled Study Followed By A Placebo-Controlled Maintenance Period And Open-Label Follow-Up To Evaluate The Efficacy And Safety Of Certolizumab Pegol In Subjects With Moderate To Severe Chronic Plaque Psoriasis - CIMPACTMedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000018190Plaque PsoriasisEUCTR2014-003492-36-GBCB Biopharma, SPR561
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Active Crohn's Diseasemoderately to severely active Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-004614-18-SKEli Lilly and Company1,150
进行中（未招募）
不适用
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerAdvanced MET-Positive Gastric, Lower Esophageal or Gastroesophageal Junction AdenocarcinomaMedDRA version: 17.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10017761Term: Gastric cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: LLTClassification code 10017766Term: Gastric cancer stage IV NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10017765Term: Gastric cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004923-11-BGAmgen Inc600